ArticleFrontiers in medicine2026
A Multidimensional approach to Severe Asthma Management: the need for Pulmonary Rehabilitation among candidates for Biologic Therapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite optimized pharmacological therapy, a significant subset of severe asthma patients remains poorly controlled. Lack of control is often driven by complex, non-inflammatory "treatable traits" that require a multidimensional management strategy beyond traditional airway targeting. Objective: To characterize clinical, functional, and inflammatory profile of severe asthma patients at the time of prescribing biologic therapy and identify potential candidates to ARM (Assessment-Rehabilitate-Maintenance) pulmonary rehabilitation (PR) program. Methods: This retrospective study analyzed 195 consecutive adults meeting GINA criteria for severe asthma admitted to our outpatient clinic between January 1, 2015, and December 31, 2025. ARM-program candidacy was predefined by the coexistence of: FEV1 < 80% predicted, mMRC ≥ 2, ACT < 20, and ≥2 annual exacerbations. Results: The median age of the cohort was 55 years and 60% of patients were female. A substantial disease burden was detected (median ACT: 16; annual exacerbations: 3). Females showed significantly higher maintenance oral corticosteroid (OCS) dependence (35.9% vs. 21.8%, Conclusions: At the time of biologic prescription, a significant proportion of severe asthma patients present a multidimensional burden, including dyspnea, frequent exacerbations, and psychological comorbidities and are potential candidates to ARM PR program. Prospective studies are needed to validate patient selection criteria and support whether pulmonary rehabilitation-may improve clinical and functional outcomes in target subgroup.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.